Skip to content

NU-MED PLUS, INC.: 10-Q filed 2024-11-14

What NU-MED PLUS, INC. reported in its quarterly report filed 2024-11-14 (fiscal Q3 2024): 26 published measures, 86 facts as tagged in accession 0001548123-24-000130.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-14
Fiscal period
fiscal Q3 2024
Accession
0001548123-24-000130 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NU-MED PLUS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-306,841USD
At 2023-12-3113,456USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-30211,382USD
At 2023-12-31160,207USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-30-204,541USD
At 2024-06-30-185,864USD
At 2024-03-31-168,577USD
At 2023-12-31-146,751USD
At 2023-09-30-131,955USD
At 2023-06-30-115,549USD
At 2023-03-31-91,229USD
At 2022-12-31-63,025USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-18,677USD92
2024-01-01 to 2024-09-30-57,790USD274
2024-04-01 to 2024-06-30-17,287USD91
2024-01-01 to 2024-03-31-21,826USD91
2023-07-01 to 2023-09-30-16,406USD92
2023-01-01 to 2023-09-30-68,930USD273
2023-04-01 to 2023-06-30-24,320USD91
2023-01-01 to 2023-03-31-28,204USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-2,765USD274
2023-01-01 to 2023-09-30-62,107USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-9,882,777USD
At 2023-12-31-9,824,987USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-3081,348,469shares92
2024-01-01 to 2024-09-3081,348,469shares274
2023-07-01 to 2023-09-3081,348,469shares92
2023-01-01 to 2023-09-3081,348,469shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-3081,348,469shares92
2024-01-01 to 2024-09-3081,348,469shares274
2023-07-01 to 2023-09-3081,348,469shares92
2023-01-01 to 2023-09-3081,348,469shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-300USD/shares92
2024-01-01 to 2024-09-300USD/shares274
2023-07-01 to 2023-09-300USD/shares92
2023-01-01 to 2023-09-300USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-300USD/shares92
2024-01-01 to 2024-09-300USD/shares274
2023-07-01 to 2023-09-300USD/shares92
2023-01-01 to 2023-09-300USD/shares273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-17,417USD92
2024-01-01 to 2024-09-30-54,037USD274
2023-07-01 to 2023-09-30-15,146USD92
2023-01-01 to 2023-09-30-65,190USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-306,841USD
At 2023-12-3113,456USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-30211,382USD
At 2023-12-31160,207USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-09-3019,850USD
At 2023-12-318,089USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-3017,417USD92
2024-01-01 to 2024-09-3054,037USD274
2023-07-01 to 2023-09-3015,146USD92
2023-01-01 to 2023-09-3065,190USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-3083,548,469shares
At 2023-12-3183,548,469shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-09-304,041USD
At 2023-12-316,806USD
At 2023-09-3011,088USD
At 2022-12-3173,195USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-309,594,687USD
At 2023-12-319,594,687USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2024-09-3083,893USD
At 2023-12-3190,368USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-09-3083,893USD
At 2023-12-3190,368USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-09-3017,053USD
At 2023-12-316,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-18,677USD92
2024-01-01 to 2024-09-30-57,790USD274
2023-07-01 to 2023-09-30-16,406USD92
2023-01-01 to 2023-09-30-68,930USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-309,467USD92
2024-01-01 to 2024-09-3028,287USD274
2023-07-01 to 2023-09-308,846USD92
2023-01-01 to 2023-09-3021,835USD273

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,260USD92
2024-01-01 to 2024-09-303,753USD274
2023-07-01 to 2023-09-301,260USD92
2023-01-01 to 2023-09-303,740USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-1,260USD92
2024-01-01 to 2024-09-30-3,753USD274
2023-07-01 to 2023-09-30-1,260USD92
2023-01-01 to 2023-09-30-3,740USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-3011,761USD274
2023-01-01 to 2023-09-30-607USD273

Inspect the source

Entity
NU-MED PLUS, INC. / CIK 0001543637
Captured
2026-09-20T09:17:46.167Z
SEC response SHA-256
69b43722f73c0160e01e320460a574e661a132d75253b9bf9ccfdf38c65e1cbf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001543637.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))